Analysis of a multiple delays model for treatment of cancer with oncolytic virotherapy (Q2332518)

From MaRDI portal

!

This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use the normal view instead:

scientific article; zbMATH DE number 7126036
Language Label Description Also known as
default for all languages
No label defined
    English
    Analysis of a multiple delays model for treatment of cancer with oncolytic virotherapy
    scientific article; zbMATH DE number 7126036

      Statements

      Analysis of a multiple delays model for treatment of cancer with oncolytic virotherapy (English)
      0 references
      0 references
      0 references
      0 references
      4 November 2019
      0 references
      Summary: Despite advanced discoveries in cancerology, conventional treatments by surgery, chemotherapy, or radiotherapy remain ineffective in some situations. Oncolytic virotherapy, i.e., the involvement of replicative viruses targeting specific tumor cells, opens new perspectives for better management of this disease. Certain viruses naturally have a preferential tropism for the tumor cells; others are genetically modifiable to present such properties, as the lytic cycle virus, which is a process that represents a vital role in oncolytic virotherapy. In the present paper, we present a mathematical model for the dynamics of oncolytic virotherapy that incorporates multiple time delays representing the multiple time periods of a lytic cycle. We compute the basic reproductive ratio \(R_0\), and we show that there exist a disease-free equilibrium point (DFE) and an endemic equilibrium point (DEE). By formulating suitable Lyapunov function, we prove that the disease-free equilibrium (DFE) is globally asymptotically stable if \(R_0 < 1\) and unstable otherwise. We also demonstrate that under additional conditions, the endemic equilibrium is stable. Also, a Hopf bifurcation analysis of our dynamic system is used to understand how solutions and their stability change as system parameters change in the case of a positive delay. To illustrate the effectiveness of our theoretical results, we give numerical simulations for several scenarios.
      0 references
      cancer treatment
      0 references
      multiple delays model
      0 references
      oncolytic virotherapy
      0 references

      Identifiers

      0 references
      0 references
      0 references
      0 references
      0 references
      0 references
      0 references